AU2003295738A1 - Novel lapachone compounds and methods of use thereof - Google Patents

Novel lapachone compounds and methods of use thereof Download PDF

Info

Publication number
AU2003295738A1
AU2003295738A1 AU2003295738A AU2003295738A AU2003295738A1 AU 2003295738 A1 AU2003295738 A1 AU 2003295738A1 AU 2003295738 A AU2003295738 A AU 2003295738A AU 2003295738 A AU2003295738 A AU 2003295738A AU 2003295738 A1 AU2003295738 A1 AU 2003295738A1
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
compound
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003295738A
Other languages
English (en)
Inventor
Samuel K. Ackerman
Zhiwel Jiang
Chiang Li
Youzhi Li
Dasharatha Reddy
June Salvesen
Xiangao Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of AU2003295738A1 publication Critical patent/AU2003295738A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003295738A 2002-11-18 2003-11-18 Novel lapachone compounds and methods of use thereof Abandoned AU2003295738A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42728302P 2002-11-18 2002-11-18
US60/427,283 2002-11-18
US10/622,854 2003-07-17
AUPCT/US03/22631 2003-07-17
PCT/US2003/037219 WO2004045557A2 (en) 2002-11-18 2003-11-18 Novel lapachone compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2003295738A1 true AU2003295738A1 (en) 2004-06-15

Family

ID=34375156

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003295738A Abandoned AU2003295738A1 (en) 2002-11-18 2003-11-18 Novel lapachone compounds and methods of use thereof

Country Status (12)

Country Link
US (1) US20040266857A1 (https=)
EP (1) EP1567515A4 (https=)
JP (1) JP2006508147A (https=)
CN (1) CN1729183A (https=)
AR (1) AR056613A1 (https=)
AU (1) AU2003295738A1 (https=)
BR (1) BR0316296A (https=)
CA (1) CA2506340A1 (https=)
EA (1) EA200500849A1 (https=)
MX (1) MXPA05005314A (https=)
TW (1) TW200510367A (https=)
WO (1) WO2004045557A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050033A2 (en) 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers
US7649013B2 (en) 2003-11-26 2010-01-19 Arqule, Inc. Methods of protecting against radiation injury
WO2005082353A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating or preventing cancer
EP2033639A2 (en) 2004-02-20 2009-03-11 Arqule, Inc. Beta-lapachone for the treatment of colon cancer
JP2007523190A (ja) * 2004-02-20 2007-08-16 アークル・インコーポレーテツド 肺癌の治療のためのβ−ラパコンの使用
EP2033638A2 (en) 2004-02-20 2009-03-11 Arqule, Inc. Beta-lapachone for the treatment of pancreatic cancer
EP1722776A2 (en) * 2004-02-20 2006-11-22 Arqule, Inc. Use of beta-lapachone as a broad spectrum anti-cancer agent
WO2005082357A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating hematologic tumors
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
EP1877097B1 (en) 2004-08-11 2012-06-20 Arqule, Inc. Aminoacid conjugates of beta-lapachone for tumor targeting
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
US20060204981A1 (en) 2005-01-07 2006-09-14 Chiang Li Compositions for modulation of PARP and methods for screening for same
WO2006128120A2 (en) * 2005-05-26 2006-11-30 Arqule, Inc. Novel lapachone compounds and methods of use thereof
JP2009538298A (ja) * 2006-05-26 2009-11-05 アークル インコーポレイテッド 新規のラパコン化合物およびその使用方法
TW200824692A (en) 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
US8389568B2 (en) 2007-03-16 2013-03-05 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
ES2532656T3 (es) 2007-04-30 2015-03-30 Arqule, Inc. Compuestos de hidroxi sulfonato de quinona y sus usos
US8067459B2 (en) 2007-10-16 2011-11-29 Arqule, Inc. Lapachone compounds and methods of use thereof
KR101405823B1 (ko) 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
KR20090073381A (ko) * 2007-12-31 2009-07-03 주식회사 머젠스 심장질환의 치료 및 예방을 위한 약제 조성물
RU2016140440A (ru) * 2010-06-01 2018-12-14 Белле-Эйр Фрейгренсиз, Инк. Способ и продукт для борьбы с запахом изо рта
WO2017106624A1 (en) 2015-12-18 2017-06-22 The Board Of Regents Of The University Of Texas System Napthoquinones, pro-drugs, and methods of use thereof
KR101735275B1 (ko) 2016-12-20 2017-05-16 아주대학교산학협력단 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2011455B (en) * 1977-12-21 1982-03-03 Ici Ltd Chemical process
US5346917A (en) * 1991-06-10 1994-09-13 Sterling Winthrop Inc. Thioxanthenone antitumor agents
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
DE60031268T2 (de) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston Verfahren und zusammansetzung zur behandlung von krebs
AU2003254029A1 (en) * 2002-07-17 2004-02-02 Arqule, Inc. Activated checkpoint therapy and methods of use thereof

Also Published As

Publication number Publication date
AR056613A1 (es) 2007-10-17
EP1567515A4 (en) 2008-04-23
WO2004045557A2 (en) 2004-06-03
US20040266857A1 (en) 2004-12-30
JP2006508147A (ja) 2006-03-09
TW200510367A (en) 2005-03-16
BR0316296A (pt) 2005-12-13
WO2004045557A3 (en) 2004-08-12
CN1729183A (zh) 2006-02-01
CA2506340A1 (en) 2004-06-03
EA200500849A1 (ru) 2006-02-24
EP1567515A2 (en) 2005-08-31
MXPA05005314A (es) 2005-10-19

Similar Documents

Publication Publication Date Title
AU2003295738A1 (en) Novel lapachone compounds and methods of use thereof
EP1877097B1 (en) Aminoacid conjugates of beta-lapachone for tumor targeting
CN101805390B (zh) 一种雷公藤红素衍生物及其用途
CN102002051B (zh) 具有抗肿瘤活性的ent-6,7-开环贝壳杉烯型冬凌草甲素衍生物、其制备方法及用途
DE69913697T2 (de) Naphtho- und dihydrobenzothiophenderivate als cytotoxische antitumormittel
EP1551392A2 (en) Novel lapacho compounds and methods of use thereof
AU2005316739A1 (en) Spiro derivatives as lipoxygenase inhibitors
CA2685739C (en) Hydroxy sulfonate of quinone compounds and their uses
JPS61158978A (ja) 抗緑内障剤としての置換芳香族スルホンアミド類
JP2011528691A (ja) 血管拡張活性を有する硝酸イソソルビド
WO2009051752A1 (en) Novel lapachone compounds and methods of use thereof
KR20050089007A (ko) 신규한 라파콘 화합물 및 이의 사용 방법
US7902354B2 (en) Lapachone compounds and methods of use thereof
WO2001017988A1 (en) Novel chalcones
WO2018153328A1 (zh) 双黄酮-铁配合物及其制备方法和应用
WO2006128120A2 (en) Novel lapachone compounds and methods of use thereof
WO2015104298A2 (de) Polyphenol-konjugate
ES2283649T3 (es) Compuesto retinoides heterociclicos.
CN101115734A (zh) 作为脂氧化酶抑制剂的螺环衍生物
HK1139411B (en) Hydroxy sulfonate of quinone compounds and their uses
EP0450588A1 (de) Substituierte 3-Thia- bzw. 3-Oxa-alkyl-Flavone, Verfahren zu ihrer Herstellung, Verwendung derselben, Arzneimittel auf Basis dieser Verbindungen sowie Zwischenprodukte
AU2002363170A1 (en) Heterocyclic retinoid compounds

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period